Unicycive Regains Nasdaq Compliance After Stock Split

Unicycive Therapeutics ( (UNCY) ) has shared an announcement.

On July 8, 2025, Unicycive Therapeutics announced it regained compliance with Nasdaq’s minimum share price requirement following a reverse stock split effective June 20, 2025. This compliance ensures the company’s continued listing on Nasdaq, potentially stabilizing its market position and reassuring stakeholders.

The most recent analyst rating on (UNCY) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Unicycive Therapeutics stock, see the UNCY Stock Forecast page.

Spark’s Take on UNCY Stock

According to Spark, TipRanks’ AI Analyst, UNCY is a Underperform.

Unicycive Therapeutics has significant financial challenges, including ongoing net losses and a reliance on debt for financing, which weigh heavily on its stock score. The technical analysis reveals a bearish trend, as the stock is trading below major moving averages. Valuation metrics further dampen the attractiveness of the stock due to negative profitability indicators. Without earnings call insights or recent corporate events to improve prospects, the overall score reflects these financial and technical weaknesses.

To see Spark’s full report on UNCY stock, click here.

More about Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company focused on developing novel treatments for kidney diseases. Its lead investigational treatment, oxylanthanum carbonate, is a phosphate binding agent under FDA review for treating hyperphosphatemia in dialysis patients with chronic kidney disease. Another investigational treatment, UNI-494, targets conditions related to acute kidney injury and has orphan drug designation for preventing Delayed Graft Function in kidney transplant patients.

Average Trading Volume: 580,608

Technical Sentiment Signal: Sell

Current Market Cap: $59.88M

For a thorough assessment of UNCY stock, go to TipRanks’ Stock Analysis page.